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Abstract
Current therapy for acute renal failure continues to have an exceedingly high mortality rate, exceeding 50% even
with dialytic or hemofiltrative support. Current renal replacement therapy in ARF only substitutes for filtration
function of the kidney but not its cellular metabolic functions. Replacing these metabolic functions may optimize
current therapy for this devastating disease process. In this regard, a renal tubule assist device (RAD) has been
developed to be placed in an extracorporeal continuous hemoperfusion circuit in series with a hemofilter. The
RAD consists of porcine renal proximal tubule cells grown as confluent monolayers in a multifiber bioreactor
with a membrane surface area from 0.4 to 1.6 m2. The cells along the inner surface of the hollow fibers are
immunoprotected from the patient’s blood by the hollow fiber membrane.In vitro experiments demonstrate that
this device possesses differentiated renal transport, metabolic and endocrinologic properties. These properties, in
fact, are responsive to normal physiological regulatory parameters. In preliminary experiments in uremic dogs,
this device has also been shown to tolerate a uremic environment while providing reabsorptive, metabolic, and
endocrinologic activity. Pilot human trials of the RAD are anticipated within the next year to improve current renal
replacement therapy in this devastating disease process.
Introduction
The improved understanding of the cellular and mole-
cular basis of organ function and disease has been
translated during the last two decades into new di-
agnostic and therapeutic approaches to a wide range
of disease processes including renal failure. A whole
new biotechnology industry has evolved to translate
this knowledge in basic biological sciences into more
effective therapeutic and diagnostic modalities. Some
notable successes have ensued. The most success-
ful applications of biotechnology to date have been
to apply recombinant genetic engineering to produce
new pharmacological agents. This method consists
of identifying a disease due to a lack of a single
protein made by cells, isolating the gene for this pro-
tein, and finally using recombinant molecular biologic
techniques to introduce the gene into an expression
system to produce large amounts of the gene prod-
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uct. Both erythropoietin and human insulin have been
produced in this manner. Although this approach has
been proven successful, the opportunities to use such a
strategy are limited, as many physiological responses
are due to a complex interaction of a series of cell
products rather than to a lack of one component.
In such situations, in which the desired effect is
dependent on an array of cell products, a possible
solution is the development of a more complex ap-
proach using ‘cell therapy’. Cell therapy is based on
the concept that specific cells can be culturedin vitro
to perform differentiated biological tasks. The sim-
plest manifestation of cell therapy is to implant living
cells to produce a natural hormone or protein in short
supply as a result of disease, usually with a regulatable
element to a biological signal (Humes, 1997). Oxygen
regulation of erythropoietin production and glucose
control over insulin secretion are notable examples.
The use of cells as gene-product delivery vehicles
is another application of cell therapy. The ability to
2
grow and expand cellsin vitro allows for efficient
transfection or transduction of a targeted gene into a
population of cells grown in tissue culture. The in-
troduction of these transduced cells into a recipient
allows for the production of a gene product that the
patient lacks or that is present in an abnormal form.
The development of immunocapsulation techniques
will allow the use of heterologous cells (Tai, 1993).
The genes for coagulation factors VIII and IX are
two examples of the potential treatment of the genetic
diseases of hemophilia A and B.
A final technology has been termed ‘tissue en-
gineering’, a developing field in which techniques
from the biological and engineering sciences are com-
bined to create structures that mimic the functions of
human organs (Langer, 1993). The majority of ap-
plications currently envisioned for tissue engineering
involve placing modified animal or human cells within
an artificial construct. Current efforts are focused on
producing bioartificial organs using cells seeded on
hollow-fiber bioreactors perfused in an extracorporeal
circuit using modified dialysis equipment. Pilot human
studies have already taken place, with an extracor-
poreal liver-assist device designed to replace hepatic
function while waiting for the patient’s own liver to
regenerate after an acute insult (Sussman et al., 1994).
Given the successes of renal replacement therapy in
the last four decades, a natural application of tissue
engineering is in the treatment of acute and chronic
renal failure.
Acute renal failure
Acute renal failure (ARF) is a result of toxic or is-
chemic insults to the kidney. It is a common disor-
der affecting nearly 200,000 patients per year in the
United States (Lake, 1994; Thadhani et al., 1996). It
presents as a devastating clinical disorder with whole
organ failure occurring within days of the initiating
injurious event. The patients with this condition are
gravely ill, requiring intensive care unit care.
Current therapy for ischemic or toxic acute renal
failure, or acute tubular necrosis (ATN), is predom-
inantly supportive in nature. The therapeutic goals
are the maintenance of fluid and electrolyte balance,
adequate nutrition, and, when present, treatment of
infection and uremia. Uremia is treated with either in-
termittent hemodialysis or continuous hemofiltration.
Although this approach has had substantial impact on
this disease process over the past 40 years, patients
with ATN still have an exceedingly high mortality rate
of greater than 50%, even with dialytic or filtrative
support. The precise reason for this mortality rate in
the face of normal electrolyte and fluid balances, and
a nonuremic condition, is unclear.
Perhaps an explanation for this high mortality
rate resides in the recognition that hemodialysis or
hemofiltration only substitutes for the filtration func-
tion of the kidney but does not replace the homeostatic,
regulatory, metabolic, and endocrine functions of the
kidney. Review of the causes of death in patients suf-
fering from ATN demonstrates that the single factor
most responsible for death was development of dis-
seminated bacterial infection due to impairment of
host defense (Lordon, 1972; Whelton, 1969). This
impairment is likely the result of the loss of cellu-
lar metabolic function of the kidney rather than lost
filtrative function. Accordingly, the development of
cell therapy modalities replacing these reabsorptive,
synthetic, metabolic, and endocrinologic functions of
the kidney may add significant value to the current
suboptimal supportive options available to treat es-
tablished ARF. An approach to this form of therapy
is the development of a bioartificial tubule to re-
place these functions and to optimize current treatment
modalities.
Bioartificial renal tubule
Critical to providing organ function replacement
through cell therapy is the need for the isolation and
growth in vitro of specific cells from adult tissue.
These cells are those that possess stem cell-like char-
acteristics with a high capacity for self-renewal and
the ability to differentiate under defined conditions
into specialized cells to develop correct structure and
functional components of a physiologic organ system
(Hall, 1989; Potten, 1990). Recent data by our labo-
ratory have demonstrated methodology to isolate and
grow renal proximal tubule progenitor cells from adult
mammalian kidneys (Humes et al., 1996; Humes,
1992). These studies were promoted by the clinical
and experimental observations suggesting that renal
proximal tubule progenitor cells must exist, as tubule
cells have the ability to regenerate after severe nephro-
toxic or ischemic injury to form a fully functional and
differentiated epithelium.
In this regard, the adult mammalian kidney tubule
epithelium exists in a relatively dormant, slowly repli-
cative state, but has a large potential for regenerative
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morphogenesis following severe ischemic or toxic in-
jury. Under selective serum-free growth conditions,
which included epidermal growth factor and retinoic
acid, a subpopulation of renal proximal tubule cells
isolated from adult rabbit kidney were grown in cell
culture. This report defines conditions in which to
selectively grow from adult mammalian kidney a sub-
population of cells with an ability to differentiate mor-
phogenically and with a high capacity for replication.
Under the growth conditions of these experiments,
these cells were able to both differentiate individually
into a renal proximal tubule cell phenotype with cell
polarity, apical microvilli, and tight junctional com-
plexes between cells along the luminal border and to
pattern form collectively into cylindrical arrays of cell
monolayers surrounding a centralized lumen. These
cells also were shown to have a high capacity for self-
renewal. Genetic marking of the cells with a recom-
binant retrovirus and dilution analysis demonstrated
that in vitro tubulogenesis often arose from clonal ex-
pansion of a single genetically tagged progenitor cell.
These tubules were derived from tubule cells grown in
primary culture and serial passages (at least 4 repli-
cation cycles) before suspension into collagen gels.
Because many tubules in the collagen gel contained
as many as 150 cells (at least 7 replication cycles),
these findings demonstrate thatin vitro tubulogenesis
arose from clonal expansion of a single cell with the
ability to undergo at least 11 replication cycles. These
results suggest that a population of proximal tubule
progenitor cells exist within the adult kidney in a rela-
tively dormant, slowly replicative state but with a rapid
potential to proliferate, differentiate, and pattern form
to regenerate the lining proximal tubule epithelium of
the kidney following severe ischemic or toxic injury
commonly seen in clinical situations.
The bioartificial renal tubule is clearly feasible
when conceived as a combination of living cells sup-
ported on polymeric substrata. A bioartificial tubule
uses epithelial progenitor cells cultured on water and
soluble-permeable hollow fiber membranes seeded
with various biomatrix materials, such that expres-
sion of differentiated vectorial transport, metabolic,
and endocrine function is attained. With appropri-
ate membranes and biomatrices, immunoprotection
of cultured progenitor cells can be achieved concur-
rently with long-term functional performance as long
as conditions support tubule cell viability (Humes,
1997; Cieslinski, 1994). The technical feasibility of
an implantable epithelial cell system derived from
cells grown as confluent monolayers along the luminal
surface of polymeric hollow fibers has been recently
achieved (McKay, 1998).
As a first step towards developing a tissue engi-
neered renal tubule assist device, Madin-Darby Canine
Kidney (MDCK) cells, a permanent renal epithelial
cell line, were seeded into the lumen of single hollow
fibers (McKay, 1998). Functional confluence of the
cells was demonstrated by the recovery of intralumi-
nally perfused14C-inulin, which averaged greater than
98.9%, versus less than 7.4% with the control non-
cell hollow fibers under identical pressure and flow
conditions. The baseline absolute fluid transport rate
averaged 1.4±0.4 µL 30 min−1. To test the depen-
dency of fluid flux with oncotic and osmotic pressure
differences across the bioartificial tubule, albumin was
added to the extracapillary space followed by addi-
tion of ouabain, an inhibitor of Na+K+ATPase, the
enzyme responsible for active transport across the
renal epithelium. Addition of albumin resulted in a
significant increase in volume transport to 4.5±1.0
µL 30 min−1. Addition of ouabain inhibited trans-
port back to baseline levels of 2.1±0.4µL 30 min−1.
These results were the first demonstration that renal
epithelial cells could be successfully grown as a con-
fluent monolayer along a hollow fiber and developed
functional active transport capabilities.
Bioartificial renal tubule assist device: In vitro
performance
The next step in the development of a bioartificial re-
nal tubule assist device (RAD) is to scale up from this
single hollow fiber renal tubule to a multifiber biore-
actor with renal proximal tubule cells that maintain
not only transport properties, but also differentiated
metabolic and endocrine functions. To accomplish this
next step, a reliable tissue source for renal progeni-
tor cells is required. Although successful renal tubule
progenitor cell expansion has been achieved with hu-
man adult kidneys, a nonhuman animal tissue source
for tubule cells has been strongly considered. Because
an expensive screening process for infectious agents
must be accomplished to ensure the safety of a human
donor source of tissue along with the lack of con-
sistent access and procurement of human tissue, an
animal tissue source for renal tubule cells for RAD
construction has been elected to be developed. The
short-term use of this device for acute therapy in the
intensive care unit (ICU) setting allows a nonhuman
tissue source as a preferred strategy. For economic and
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safety concerns, pigs can be used as a tissue source
for this extracorporeal short-term RAD. Because of its
anatomic and physiological similarities with humans
and the relative simplicity with which it can be bred
in large numbers, the pig is currently considered the
best source of organs for both human xenotransplanta-
tion and immunoisolated cell therapy devices (Cozzi,
1995; Cooper et al., 1991; Calne, 1970). Kidneys are
taken from 4–6 week old Yorkshire breed pigs. A full
clinical profile of each donor pig for pathogens and
blood and tissue pathology is accomplished to ensure
the safety and noninfectivity of donor tissue. From
these kidneys, renal proximal tubule segments are iso-
lated and renal tubule progenitor cells are expanded
with techniques previously described (Humes et al.,
1996; Humes, 1992).
Further experiments are now under way to scale up
to a clinically applicable device with the use of com-
mercially available high-flux hollow fiber cartridges.
Preliminary experiments have tested transport and
metabolic functions of these cells grown intralumi-
nally within these cartridges with membrane surface
areas of from 97 cm2 to 1.6 m2. Starting with a high
flux hemofilter cartridge, the intraluminal surface of
the hollow fibers were coated with laminin. Renal
tubule cells were then seeded at a density of 105 cells
mL−1 into the intracapillary space with four cell in-
fusions separated by 30 min and a 90◦ rotation of
the cartridge. The seeded cartridge was connected to
the bioreactor perfusion system, in which the extra-
capillary space was filled with culture media and the
intracapillary space perfused with similar media at a
rate of 4–5 mL hr−1. Culture media, both intracapil-
lary and extracapillary, were changed every 2–3 days
to maintain adequate metabolic substrates for growth.
After 7 to 14 days of growth, the unit was studied. Pre-
liminary in vitro experiments utilizing porcine renal
proximal tubule progenitor cells have clearly shown
differentiated transport and metabolic function of the
RAD unit as summarized in Table I.
Of importance, the transport properties were in-
hibitable by specific inhibitors–ouabain for active
sodium transport, phlorizin for active glucose trans-
port, probenecid for para-aminohippuric acid (PAH)
secretion, and acivicin for glutathione transport and
metabolism. The metabolic processes of the RAD also
demonstrated sensitivity to normal physiological vari-
ables: ammoniagenesis was pH sensitive and vitamin
D3 activation was PTH and phosphate sensitive. The
absolute values of these various functions and respon-
sivity to inhibitors and physiologic modulators are
detailed in the attached data summary.
Ex vivo performance of the RAD
While assessing the functionality of a RAD unitin
vitro is an important component of bioreactor design,
the true test of functionality and utility comes in test-
ing the devicein vivo, or ex vivo. Before clinical trials
can be undertaken with such a device, extensive testing
must be done in large animals, where the system can
be evaluated under physiologic conditions and can be
optimized for functionality and ease of use. The renal
assist device will be used as a component in an extra-
corporeal circuit, where care must be taken to ensure
proper operating conditions. Conditions under opera-
tion should mimic, as best as possible, those that the
cells in the device are accustomed to seeing physio-
logically or in vitro. Important parameters to monitor
and adjust are, for example, flow rates, pressures, and
temperature.
The bioartificial kidney set-up consists of a fil-
tration device (a conventional hemofilter) followed in
series by the tubule unit. Specifically, blood is pumped
out of a large animal using a peristaltic pump. The
blood then enters the fibers of a hemofilter, where
ultrafiltrate is formed and flows to the RAD down-
stream to the hemofilter. Processed ultrafiltrate exiting
the RAD is collected and can be discarded as ‘urine.’
The filtered blood exiting the hemofilter enters the
RAD through the extracapillary space (ECS) port and
disperses among the fibers of the device. Upon exit
of the RAD, the processed blood is delivered back to
the animal. This additional pump is required to main-
tain appropriate hydraulic pressures within the RAD.
In this regard, the pressure of the blood and ultrafil-
trate just before entry into the RAD are monitored.
Heparin is delivered continuously into the blood prior
to entering the RAD to diminish clotting within the
device. The RAD is oriented horizontally and placed
into a temperature controlled environment. The tem-
perature of the cell compartment of the RAD must be
maintained at 37◦C throughout its operation to en-
sure optimal functionality of the cells. Maintenance
of a physiologic temperature is a critical factor in the
functionality of the RAD.
The tubule unit is able to maintain viability, be-
cause metabolic substrates and low-molecular weight
growth factors are delivered to the tubule cells from
the ultrafiltration unit and the blood in the ECS. Fur-
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Table 1. In vitrofunctional characteristics of the renal assist device (RAD)
Transport Metabolic
Fluid reabsorption Ammoniagenesis




Acetazolamide inhibition Glutathione synthesis
Glucose reabsorption
Phlorizin inhibition Endocrinologic
PAH secretion 1,25-Dihydroxyvitamin D3 activation
Probenecid inhibition PTH enhancement
Phosphate inhibition
thermore, immunoprotection of the cells grown within
the hollow fiber is achieved due to the impenetrance
of immunoglobulins and immunologically competent
cells through the hollow fiber if the encapsulating
membrane has a pore size which excludes compounds
with a molecular weight greater than 150,000 Da. Re-
jection of these cells will, therefore, not occur. This
arrangement thereby allows the filtrate to enter the in-
ternal compartments of the hollow fiber network, lined
with confluent monolayers of renal tubule cells for
regulated transport and metabolic function.
The use of such a device in uremic and non-uremic
large animals has shown that inulin leak rates in-
creased by a few percentage points from less than
5–10% to slightly greater than 10% immediately after
use, but returned to pre-study values after being main-
tained in culture for two weeks, meaning cells remain
viable and can continue growing. The use of scaled-
up cartridges can increase metabolic production. A
surface area expansion from 0.4 to 0.8 m2 results in an
increase in the number of cells from 2× 109 to 4× 109
cells. Of note, RAD cartridges have been maintained
in culture in excess of two months after use in large
animal studies.
With the development of this extracorporeal circuit
and design considerations, preliminary studies have
been completed. Dogs weighing approximately 25 kg
were placed on a controlled, low protein diet five days
prior to being made uremic by performing bilateral
nephrectomies. A double lumen catheter was placed
into the internal jugular vein, extending into the heart,
and sutured into place on the skin to prevent dislodg-
ment. After 24 hr of post-operative recovery, the dogs
were treated either with hemofiltration and the RAD or
with hemofiltration and a control cartridge containing
no cells. Dogs were treated daily for either 7 or 9 hr
for 3 days or for 24 hr continuously. Preliminaryex
vivo experiments in these uremic dogs have demon-
strated that the RAD performs differentiated transport,
metabolic and endocrinologic function characteristic
of the proximal tubulein vivo.
The successful completion of proven functional
performance of the RAD in uremic dogs prepares for
the progression of the testing of this device in hu-
man subjects. Upon Food and Drug Administration
(FDA) approval for an IND, a phase I/II trial is planned
for safety and toxicity studies followed by a full
controlled phase III efficacy clinical trial. Before pro-
ceeding to human clinical trials, the FDA, the Centers
for Disease Control and Prevention (CDC) and the Na-
tional Institutes of Health (NIH) are currently develop-
ing new requirement before allowing human studies to
proceed. The need for newer requirements and safe-
guards were mandated with the discovery that pigs,
the favored donor animal, contain porcine endogenous
retroviruses (PERV) which can, under selected con-
ditions, infect human cells (LeTissier et al., 1997).
The technology described in this report, however, has
much less risk than xenotransplantation (animal-to-
human solid organ transplantation) due to the short ex-
posure time, the immunoisolation of the cells, and the
use of the RAD in non-immunosuppressed patients.
The ability to proceed with these clinical studies will
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be dependent upon meeting the soon-to-be-established
safeguards for animal-to-human cell therapy.
Added value of the RAD to current therapy
Current therapy for ischemic or toxic ARF is predom-
inantly supportive in nature. The therapeutic goals are
the maintenance of fluid and electrolyte balance, ade-
quate nutrition, and treatment of infection and uremia
when they are present. Uremia is treated with either in-
termittent hemodialysis or continuous hemofiltration.
Although this approach over the last 40 yr has had
substantial impact on this disease process, patients
with ATN still have an exceedingly high mortality of
greater than 50%, even with dialytic or hemofiltrative
support (Thadhani, 1996; Humes, 1995). Perhaps an
explanation for this high mortality is that hemodialy-
sis or hemofiltration only substitutes for the filtration
function of the kidney and does not replace the home-
ostatic, regulatory, metabolic, and endocrine functions
of the kidney. Review of the causes of death in pa-
tients suffering from ATN demonstrated that the single
factor most responsible for death was development of
infection. These infectious complications, with result-
ing sepsis and septic shock, may develop in ATN due
to the loss of the nonfiltrative and metabolic functions
of the kidney.
The kidney not only is important as an excretory
organ but provides important resorptive, homeostatic,
metabolic, and endocrinological functions. There are
multiple renal cellular functions that the RAD may
provide to a patient with ATN which may be important
in preventing the septic complications of this disorder.
Three key examples can be provided to demonstrate
this added value.
The loss of both glutathione synthetic function and
production of key free-radical scavenging enzymes
in renal failure undoubtedly diminishes host defense
function (Dröge et al., 1994; Avissar et al., 1994)
and contributes to the pathogenesis of septic shock
(Kinscherf et al., 1994; Zimerman, 1995). Increas-
ing evidence demonstrates that the redox state within
immunocompetent cells critically regulates immuno-
logically relevant genes so that the balance between
glutathione (GSH) and glutathione disulfide (GSSG)
regulates these processes. This evidence clearly sup-
ports the concept that GSH is a key limiting factor
that determines the magnitude of immunologic func-
tions both in vitro and in vivo, thereby playing an
important role in host defense. GSH depletion may
well be responsible for the induction of immunologic
nonresponsiveness under conditions of antigenic stim-
ulation (Dröge et al., 1994). Even a small depletion
of intracellular glutathione pool alters dramatically
the process of myeloblast transformation, prolifera-
tion, and cytotoxic T-cell generation (Kinscherf et al.,
1994).
A variety of studies have clearly demonstrated
that excessive free radical generation contributes to
the vascular and tissue damage in sepsis. The sepsis
syndrome triggers a complex series of coagulation,
complement and cytokine cascades to defend against
bacterial invasion (Zimerman, 1995). Overwhelming
sepsis, however, results in excessive host defense
responses, including neutrophil activation with exces-
sive release of free radicals (Goode, 1993). Since the
action of free radicals is normally limited by antiox-
idant defense systems, in which GSH/GSSG axis is
central, it is not surprising that GSH was protective
to oxidant injury and improved the hemodynamic and
metabolic derangements in both experimental animal
and clinical studies of sepsis (Goode, 1993; Lash et
al., 1986).
In this regard, the kidney plays an integral role in
glutathione metabolism of the body (Curthoys, 1983).
The initial step in glutathione turnover is its release
from the cell where it is transported to the kidney
where it is almost completely extracted and degraded
to its constituent amino acids, predominantly in the
proximal tubules. Within these epithelial cells, glu-
tathione is resynthesized and returned to the systemic
circulation. This process is so dynamic that renal glu-
tathione turnover rate has a half-life of only 30 min.
The kidney, and specifically proximal tubule cells,
are also the major source of synthesis of antioxidant
glutathione-related enzymes (Mohandas et al., 1984;
Avissar et al., 1994). The key role of the kidney in
this GSH regulatory pathway is exemplified by the fact
that renal failure patients have severely low plasma
levels of GSH and glutathione peroxidases (Avissar et
al., 1994; Ross et al., 1997) and therefore are at in-
creased risk for oxidative stress, especially in bacterial
infection.
The loss of key endocrinologic functions in ARF
may also diminish host defense to infection in patients
with this disorder. The 1-hydroxylation of 25-OH vi-
tamin D3 in the proximal tubule cells converts vitamin
D3 into its most active metabolite. Both acute and
chronic renal failure results in declines in the cir-
culating level of this active metabolite and leads to
vitamin D deficiency. A number of studies have clearly
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demonstrated that 1,25-dihydroxyvitamin D3 plays an
important role in the regulation of the immune system
(Koren et al., 1992). High affinity receptors are found
in peripheral blood lymphocytes and thymocytes and
vitamin D deficiency impairs cell mediated immu-
nity (Yang et al., 1993). Neutrophils from patients
with vitamin D deficiency have abnormal motility and
phagocytic ability (Bhalla, 1989). Administration of
vitamin D3 to patients on hemodialysis restores mi-
togen stimulated T cell responses to normal (Bikle,
1992). A critical role of cytosolic calcium in the ox-
idative burst of granulocytes has been acknowledged
(Sullivan et al., 1989). The immune system has, there-
fore, been clearly recognized to be an important target
tissue of this important hormone.
The kidney may play another role in host defense
by participating in the complex and dynamic network
of pro- and anti-inflammatory cytokines. The proximal
tubule cells derive embryonically from mesodermal
progenitors closely related to bone marrow precursor
cells and have retained many elements of immuno-
logically competent cells, including the ability for
antigen presentation and production of a variety of
immunologic active cytokines (Ong, 1994). Little has
been explored into the role of the kidney in the sep-
sis syndrome, even though this disorder is a defining
factor in the high mortality rate associated with ATN.
Septic shock is an acute syndrome that is charac-
terized by hypotension, coagulopathy, and eventual
multiorgan failure primarily to ischemic tissue injury.
This disorder is associated with dramatic elevations
in inflammatory cytokines, including tumor necrosis
factor (TNF)-α, interleukin (IL)-1 and IL-6 (Galley,
1996). This reactive and uncontrolled inflammatory
response results in the adverse hemodynamic and
metabolic disturbances in septic shock. More detailed
understanding of the pathophysiology of this process,
however, has suggested that the problem arises not
from the expression of pro-inflammatory cytokines but
the inadequate modulation by anti-inflammatory cy-
tokines (Galley, 1996). One central anti-inflammatory
mediator in this cascade is IL-10. IL-10 is a very
proximal inhibitor of the cell-mediated (Th1-type)
immune response, thereby promoting Th2-type hu-
moral immune responses (Galley, 1996; Standiford,
1997). This compound has potent anti-inflammatory
properties, including deactivation of neutrophils and
macrophages, and diminishes the production of TNF-
α, interferon-γ and members of both the C-X-C and
C-C chemokine families. In fact, endotoxemia results
in elevated plasma levels of IL-10 in response to endo-
toxin challenge in mice with lipopolysaccharide (LPS)
but the source of this IL-10 in endotoxemia is not clear
(Howard et al., 1993). The administration of IL-10 to
mice challenged with LPS protects from lethal endo-
toxemia and neutralization of IL-10 increases lethality
after LPS challenge, thereby demonstrating the impor-
tant role of IL-10 in endotoxin shock (Standiford et al.,
1995; Howard et al., 1993). The manner in which these
insights relate to the kidney in ATN is suggested by the
recent data from our laboratory that LPS exposure to
proximal tubule cells (PTC)in vitro results in substan-
tial production of IL-10 by PTC. This finding leads
to the hypothesis that ATN, which is characterized by
predominant PTC damage, may diminish the systemic
response of increased IL-10 plasma levels in response
to septic shock. This blunted IL-10 anti-inflammatory
response could then lead to worsening hemodynamic
and metabolic abnormalities in the sepsis syndrome,
incremental multiorgan failure and mortality.
For clinical usefulness, these devices must be
prefabricated with a defined and carefully screened
porcine tissue source and held in storage in cell in-
cubators. Upon request to treat a patient suffering
from acute renal failure, which develops over a three
to five day time course, the bioartificial device must
be transported similar to a transplanted organ to the
distant site for patient use. The logistics required to
successfully achieve this effort are significant but may
well be worth developing if the RAD has a significant
positive outcome on the morbidity and mortality of
acute renal failure. With the successful technological
achievements with recentin vitro andex vivoexper-
iments with this device, initial clinical studies are
planned in patients within the year.
As discussed, prior studies suggest that the kidney
and its proximal tubule cells play a critical role in
host defense and the immunologic processes respon-
sible to combat bacteriologic and viral infections. Cell
replacement therapy with an extracorporeal bioartifi-
cial renal tubule assist device (RAD), by providing
critical metabolic, endocrinologic and cytokine factors
during ARF, will hopefully result in a decrease in the
mortality rate of this devastating disorder.
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